Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Identifieur interne : 000692 ( Main/Exploration ); précédent : 000691; suivant : 000693Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Auteurs : Eric Pujade-Lauraine [France] ; Jonathan A. Ledermann [Royaume-Uni] ; Frédéric Selle [France] ; Val Gebski [Australie] ; Richard T. Penson [États-Unis] ; Amit M. Oza [Canada] ; Jacob Korach [Israël] ; Tomasz Huzarski [Pologne] ; Andrés Poveda [Espagne] ; Sandro Pignata [Italie] ; Michael Friedlander [Australie] ; Nicoletta Colombo [Italie] ; Philipp Harter [Allemagne] ; Keiichi Fujiwara [Japon] ; Isabelle Ray-Coquard [France] ; Susana Banerjee [Royaume-Uni] ; Joyce Liu [États-Unis] ; Elizabeth S. Lowe [États-Unis] ; Ralph Bloomfield [Royaume-Uni] ; Patricia Pautier [France]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Antinéoplasiques (usage thérapeutique), Chimiothérapie de maintenance, Comprimés, Femelle, Gène BRCA1, Gène BRCA2, Humains, Mutation, Méthode en double aveugle, Phtalazines (usage thérapeutique), Pipérazines (usage thérapeutique), Tumeurs de l'ovaire (anatomopathologie), Tumeurs de l'ovaire (génétique), Tumeurs de l'ovaire (traitement médicamenteux).
- MESH :
- anatomopathologie : Tumeurs de l'ovaire.
- génétique : Tumeurs de l'ovaire.
- traitement médicamenteux : Tumeurs de l'ovaire.
- usage thérapeutique : Antinéoplasiques, Phtalazines, Pipérazines.
- Adulte d'âge moyen, Chimiothérapie de maintenance, Comprimés, Femelle, Gène BRCA1, Gène BRCA2, Humains, Mutation, Méthode en double aveugle.
English descriptors
- KwdEn :
- Antineoplastic Agents (therapeutic use), Double-Blind Method, Female, Genes, BRCA1, Genes, BRCA2, Humans, Maintenance Chemotherapy, Middle Aged, Mutation, Ovarian Neoplasms (drug therapy), Ovarian Neoplasms (genetics), Ovarian Neoplasms (pathology), Phthalazines (therapeutic use), Piperazines (therapeutic use), Tablets.
- MESH :
- chemical , therapeutic use : Antineoplastic Agents, Phthalazines, Piperazines.
- drug therapy : Ovarian Neoplasms.
- genetics : Ovarian Neoplasms.
- pathology : Ovarian Neoplasms.
- Double-Blind Method, Female, Genes, BRCA1, Genes, BRCA2, Humans, Maintenance Chemotherapy, Middle Aged, Mutation, Tablets.
Abstract
Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive, relapsed high-grade serous ovarian cancer. We aimed to confirm these findings in patients with a BRCA1 or BRCA2 (BRCA1/2) mutation using a tablet formulation of olaparib.
DOI: 10.1016/S1470-2045(17)30469-2
PubMed: 28754483
Affiliations:
- Allemagne, Australie, Canada, Espagne, France, Israël, Italie, Japon, Pologne, Royaume-Uni, États-Unis
- Angleterre, Auvergne-Rhône-Alpes, Grand Londres, Lombardie, Maryland, Massachusetts, Nouvelle-Galles du Sud, Rhône-Alpes, Île-de-France
- Londres, Lyon, Milan, Paris, Sydney
- University College de Londres, Université Paris-Descartes, Université de Sydney
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000529
- to stream PubMed, to step Curation: 000527
- to stream PubMed, to step Checkpoint: 000527
- to stream Ncbi, to step Merge: 004C03
- to stream Ncbi, to step Curation: 004C03
- to stream Ncbi, to step Checkpoint: 004C03
- to stream Main, to step Merge: 000687
- to stream Main, to step Curation: 000692
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.</title><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation wicri:level="4"><nlm:affiliation>Medical Oncology Department, Université Paris Descartes, AP-HP, Paris, France. Electronic address: epujade@arcagy.org.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology Department, Université Paris Descartes, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris-Descartes</orgName></affiliation></author><author><name sortKey="Ledermann, Jonathan A" sort="Ledermann, Jonathan A" uniqKey="Ledermann J" first="Jonathan A" last="Ledermann">Jonathan A. Ledermann</name><affiliation wicri:level="4"><nlm:affiliation>Department of Oncology, University College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Oncology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region><settlement type="city">Londres</settlement></placeName><orgName type="university">University College de Londres</orgName></affiliation></author><author><name sortKey="Selle, Frederic" sort="Selle, Frederic" uniqKey="Selle F" first="Frédéric" last="Selle">Frédéric Selle</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Tenon, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Tenon, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Gebski, Val" sort="Gebski, Val" uniqKey="Gebski V" first="Val" last="Gebski">Val Gebski</name><affiliation wicri:level="4"><nlm:affiliation>Department of Biostatistics and Research Methodology, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Biostatistics and Research Methodology, University of Sydney, Sydney, NSW</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Penson, Richard T" sort="Penson, Richard T" uniqKey="Penson R" first="Richard T" last="Penson">Richard T. Penson</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Oza, Amit M" sort="Oza, Amit M" uniqKey="Oza A" first="Amit M" last="Oza">Amit M. Oza</name><affiliation wicri:level="1"><nlm:affiliation>Princess Margaret Cancer Centre, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Princess Margaret Cancer Centre, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Korach, Jacob" sort="Korach, Jacob" uniqKey="Korach J" first="Jacob" last="Korach">Jacob Korach</name><affiliation wicri:level="1"><nlm:affiliation>Gynecologic Oncology Department, Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Gynecologic Oncology Department, Sheba Medical Center, Tel Aviv University, Tel Hashomer</wicri:regionArea><wicri:noRegion>Tel Hashomer</wicri:noRegion></affiliation></author><author><name sortKey="Huzarski, Tomasz" sort="Huzarski, Tomasz" uniqKey="Huzarski T" first="Tomasz" last="Huzarski">Tomasz Huzarski</name><affiliation wicri:level="1"><nlm:affiliation>Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Genetics and Pathology, Pomeranian Medical University, Szczecin</wicri:regionArea><wicri:noRegion>Szczecin</wicri:noRegion></affiliation></author><author><name sortKey="Poveda, Andres" sort="Poveda, Andres" uniqKey="Poveda A" first="Andrés" last="Poveda">Andrés Poveda</name><affiliation wicri:level="1"><nlm:affiliation>Instituto Valenciano de Oncología, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto Valenciano de Oncología, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Pignata, Sandro" sort="Pignata, Sandro" uniqKey="Pignata S" first="Sandro" last="Pignata">Sandro Pignata</name><affiliation wicri:level="1"><nlm:affiliation>Istituto Tumori Pascale di Napoli, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Tumori Pascale di Napoli, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Colombo, Nicoletta" sort="Colombo, Nicoletta" uniqKey="Colombo N" first="Nicoletta" last="Colombo">Nicoletta Colombo</name><affiliation wicri:level="3"><nlm:affiliation>Gynecology Department, University of Milan-Bicocca and Istituto Europeo Oncología, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Gynecology Department, University of Milan-Bicocca and Istituto Europeo Oncología, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Harter, Philipp" sort="Harter, Philipp" uniqKey="Harter P" first="Philipp" last="Harter">Philipp Harter</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author><author><name sortKey="Fujiwara, Keiichi" sort="Fujiwara, Keiichi" uniqKey="Fujiwara K" first="Keiichi" last="Fujiwara">Keiichi Fujiwara</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama</wicri:regionArea><wicri:noRegion>Saitama</wicri:noRegion></affiliation></author><author><name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Centre Léon Bérard and University Claude Bernard, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology Department, Centre Léon Bérard and University Claude Bernard, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Banerjee, Susana" sort="Banerjee, Susana" uniqKey="Banerjee S" first="Susana" last="Banerjee">Susana Banerjee</name><affiliation wicri:level="3"><nlm:affiliation>The Royal Marsden NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Royal Marsden NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Liu, Joyce" sort="Liu, Joyce" uniqKey="Liu J" first="Joyce" last="Liu">Joyce Liu</name><affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Lowe, Elizabeth S" sort="Lowe, Elizabeth S" uniqKey="Lowe E" first="Elizabeth S" last="Lowe">Elizabeth S. Lowe</name><affiliation wicri:level="2"><nlm:affiliation>AstraZeneca, Gaithersburg, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AstraZeneca, Gaithersburg, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bloomfield, Ralph" sort="Bloomfield, Ralph" uniqKey="Bloomfield R" first="Ralph" last="Bloomfield">Ralph Bloomfield</name><affiliation wicri:level="1"><nlm:affiliation>AstraZeneca, Cambridge, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>AstraZeneca, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Pautier, Patricia" sort="Pautier, Patricia" uniqKey="Pautier P" first="Patricia" last="Pautier">Patricia Pautier</name><affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28754483</idno><idno type="pmid">28754483</idno><idno type="doi">10.1016/S1470-2045(17)30469-2</idno><idno type="wicri:Area/PubMed/Corpus">000529</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000529</idno><idno type="wicri:Area/PubMed/Curation">000527</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000527</idno><idno type="wicri:Area/PubMed/Checkpoint">000527</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000527</idno><idno type="wicri:Area/Ncbi/Merge">004C03</idno><idno type="wicri:Area/Ncbi/Curation">004C03</idno><idno type="wicri:Area/Ncbi/Checkpoint">004C03</idno><idno type="wicri:Area/Main/Merge">000687</idno><idno type="wicri:Area/Main/Curation">000692</idno><idno type="wicri:Area/Main/Exploration">000692</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.</title><author><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name><affiliation wicri:level="4"><nlm:affiliation>Medical Oncology Department, Université Paris Descartes, AP-HP, Paris, France. Electronic address: epujade@arcagy.org.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology Department, Université Paris Descartes, AP-HP, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris-Descartes</orgName></affiliation></author><author><name sortKey="Ledermann, Jonathan A" sort="Ledermann, Jonathan A" uniqKey="Ledermann J" first="Jonathan A" last="Ledermann">Jonathan A. Ledermann</name><affiliation wicri:level="4"><nlm:affiliation>Department of Oncology, University College London, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Oncology, University College London, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region><settlement type="city">Londres</settlement></placeName><orgName type="university">University College de Londres</orgName></affiliation></author><author><name sortKey="Selle, Frederic" sort="Selle, Frederic" uniqKey="Selle F" first="Frédéric" last="Selle">Frédéric Selle</name><affiliation wicri:level="3"><nlm:affiliation>Hôpital Tenon, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Tenon, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Gebski, Val" sort="Gebski, Val" uniqKey="Gebski V" first="Val" last="Gebski">Val Gebski</name><affiliation wicri:level="4"><nlm:affiliation>Department of Biostatistics and Research Methodology, University of Sydney, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Biostatistics and Research Methodology, University of Sydney, Sydney, NSW</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Penson, Richard T" sort="Penson, Richard T" uniqKey="Penson R" first="Richard T" last="Penson">Richard T. Penson</name><affiliation wicri:level="2"><nlm:affiliation>Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Oza, Amit M" sort="Oza, Amit M" uniqKey="Oza A" first="Amit M" last="Oza">Amit M. Oza</name><affiliation wicri:level="1"><nlm:affiliation>Princess Margaret Cancer Centre, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Princess Margaret Cancer Centre, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Korach, Jacob" sort="Korach, Jacob" uniqKey="Korach J" first="Jacob" last="Korach">Jacob Korach</name><affiliation wicri:level="1"><nlm:affiliation>Gynecologic Oncology Department, Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Gynecologic Oncology Department, Sheba Medical Center, Tel Aviv University, Tel Hashomer</wicri:regionArea><wicri:noRegion>Tel Hashomer</wicri:noRegion></affiliation></author><author><name sortKey="Huzarski, Tomasz" sort="Huzarski, Tomasz" uniqKey="Huzarski T" first="Tomasz" last="Huzarski">Tomasz Huzarski</name><affiliation wicri:level="1"><nlm:affiliation>Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Genetics and Pathology, Pomeranian Medical University, Szczecin</wicri:regionArea><wicri:noRegion>Szczecin</wicri:noRegion></affiliation></author><author><name sortKey="Poveda, Andres" sort="Poveda, Andres" uniqKey="Poveda A" first="Andrés" last="Poveda">Andrés Poveda</name><affiliation wicri:level="1"><nlm:affiliation>Instituto Valenciano de Oncología, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto Valenciano de Oncología, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Pignata, Sandro" sort="Pignata, Sandro" uniqKey="Pignata S" first="Sandro" last="Pignata">Sandro Pignata</name><affiliation wicri:level="1"><nlm:affiliation>Istituto Tumori Pascale di Napoli, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Istituto Tumori Pascale di Napoli, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology, University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Colombo, Nicoletta" sort="Colombo, Nicoletta" uniqKey="Colombo N" first="Nicoletta" last="Colombo">Nicoletta Colombo</name><affiliation wicri:level="3"><nlm:affiliation>Gynecology Department, University of Milan-Bicocca and Istituto Europeo Oncología, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Gynecology Department, University of Milan-Bicocca and Istituto Europeo Oncología, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Harter, Philipp" sort="Harter, Philipp" uniqKey="Harter P" first="Philipp" last="Harter">Philipp Harter</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen</wicri:regionArea><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion><wicri:noRegion>Essen</wicri:noRegion></affiliation></author><author><name sortKey="Fujiwara, Keiichi" sort="Fujiwara, Keiichi" uniqKey="Fujiwara K" first="Keiichi" last="Fujiwara">Keiichi Fujiwara</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama</wicri:regionArea><wicri:noRegion>Saitama</wicri:noRegion></affiliation></author><author><name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Centre Léon Bérard and University Claude Bernard, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology Department, Centre Léon Bérard and University Claude Bernard, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Banerjee, Susana" sort="Banerjee, Susana" uniqKey="Banerjee S" first="Susana" last="Banerjee">Susana Banerjee</name><affiliation wicri:level="3"><nlm:affiliation>The Royal Marsden NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Royal Marsden NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Liu, Joyce" sort="Liu, Joyce" uniqKey="Liu J" first="Joyce" last="Liu">Joyce Liu</name><affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Lowe, Elizabeth S" sort="Lowe, Elizabeth S" uniqKey="Lowe E" first="Elizabeth S" last="Lowe">Elizabeth S. Lowe</name><affiliation wicri:level="2"><nlm:affiliation>AstraZeneca, Gaithersburg, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>AstraZeneca, Gaithersburg, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bloomfield, Ralph" sort="Bloomfield, Ralph" uniqKey="Bloomfield R" first="Ralph" last="Bloomfield">Ralph Bloomfield</name><affiliation wicri:level="1"><nlm:affiliation>AstraZeneca, Cambridge, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>AstraZeneca, Cambridge</wicri:regionArea><wicri:noRegion>Cambridge</wicri:noRegion></affiliation></author><author><name sortKey="Pautier, Patricia" sort="Pautier, Patricia" uniqKey="Pautier P" first="Patricia" last="Pautier">Patricia Pautier</name><affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (therapeutic use)</term><term>Double-Blind Method</term><term>Female</term><term>Genes, BRCA1</term><term>Genes, BRCA2</term><term>Humans</term><term>Maintenance Chemotherapy</term><term>Middle Aged</term><term>Mutation</term><term>Ovarian Neoplasms (drug therapy)</term><term>Ovarian Neoplasms (genetics)</term><term>Ovarian Neoplasms (pathology)</term><term>Phthalazines (therapeutic use)</term><term>Piperazines (therapeutic use)</term><term>Tablets</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Chimiothérapie de maintenance</term><term>Comprimés</term><term>Femelle</term><term>Gène BRCA1</term><term>Gène BRCA2</term><term>Humains</term><term>Mutation</term><term>Méthode en double aveugle</term><term>Phtalazines (usage thérapeutique)</term><term>Pipérazines (usage thérapeutique)</term><term>Tumeurs de l'ovaire (anatomopathologie)</term><term>Tumeurs de l'ovaire (génétique)</term><term>Tumeurs de l'ovaire (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Phthalazines</term><term>Piperazines</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs de l'ovaire</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Tumeurs de l'ovaire</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs de l'ovaire</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Phtalazines</term><term>Pipérazines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term><term>Female</term><term>Genes, BRCA1</term><term>Genes, BRCA2</term><term>Humans</term><term>Maintenance Chemotherapy</term><term>Middle Aged</term><term>Mutation</term><term>Tablets</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Chimiothérapie de maintenance</term><term>Comprimés</term><term>Femelle</term><term>Gène BRCA1</term><term>Gène BRCA2</term><term>Humains</term><term>Mutation</term><term>Méthode en double aveugle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive, relapsed high-grade serous ovarian cancer. We aimed to confirm these findings in patients with a BRCA1 or BRCA2 (BRCA1/2) mutation using a tablet formulation of olaparib.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Israël</li><li>Italie</li><li>Japon</li><li>Pologne</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Auvergne-Rhône-Alpes</li><li>Grand Londres</li><li>Lombardie</li><li>Maryland</li><li>Massachusetts</li><li>Nouvelle-Galles du Sud</li><li>Rhône-Alpes</li><li>Île-de-France</li></region><settlement><li>Londres</li><li>Lyon</li><li>Milan</li><li>Paris</li><li>Sydney</li></settlement><orgName><li>University College de Londres</li><li>Université Paris-Descartes</li><li>Université de Sydney</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Pujade Lauraine, Eric" sort="Pujade Lauraine, Eric" uniqKey="Pujade Lauraine E" first="Eric" last="Pujade-Lauraine">Eric Pujade-Lauraine</name></region><name sortKey="Pautier, Patricia" sort="Pautier, Patricia" uniqKey="Pautier P" first="Patricia" last="Pautier">Patricia Pautier</name><name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name><name sortKey="Selle, Frederic" sort="Selle, Frederic" uniqKey="Selle F" first="Frédéric" last="Selle">Frédéric Selle</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Ledermann, Jonathan A" sort="Ledermann, Jonathan A" uniqKey="Ledermann J" first="Jonathan A" last="Ledermann">Jonathan A. Ledermann</name></region><name sortKey="Banerjee, Susana" sort="Banerjee, Susana" uniqKey="Banerjee S" first="Susana" last="Banerjee">Susana Banerjee</name><name sortKey="Bloomfield, Ralph" sort="Bloomfield, Ralph" uniqKey="Bloomfield R" first="Ralph" last="Bloomfield">Ralph Bloomfield</name></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Gebski, Val" sort="Gebski, Val" uniqKey="Gebski V" first="Val" last="Gebski">Val Gebski</name></region><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name></country><country name="États-Unis"><region name="Massachusetts"><name sortKey="Penson, Richard T" sort="Penson, Richard T" uniqKey="Penson R" first="Richard T" last="Penson">Richard T. Penson</name></region><name sortKey="Liu, Joyce" sort="Liu, Joyce" uniqKey="Liu J" first="Joyce" last="Liu">Joyce Liu</name><name sortKey="Lowe, Elizabeth S" sort="Lowe, Elizabeth S" uniqKey="Lowe E" first="Elizabeth S" last="Lowe">Elizabeth S. Lowe</name></country><country name="Canada"><noRegion><name sortKey="Oza, Amit M" sort="Oza, Amit M" uniqKey="Oza A" first="Amit M" last="Oza">Amit M. Oza</name></noRegion></country><country name="Israël"><noRegion><name sortKey="Korach, Jacob" sort="Korach, Jacob" uniqKey="Korach J" first="Jacob" last="Korach">Jacob Korach</name></noRegion></country><country name="Pologne"><noRegion><name sortKey="Huzarski, Tomasz" sort="Huzarski, Tomasz" uniqKey="Huzarski T" first="Tomasz" last="Huzarski">Tomasz Huzarski</name></noRegion></country><country name="Espagne"><noRegion><name sortKey="Poveda, Andres" sort="Poveda, Andres" uniqKey="Poveda A" first="Andrés" last="Poveda">Andrés Poveda</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Pignata, Sandro" sort="Pignata, Sandro" uniqKey="Pignata S" first="Sandro" last="Pignata">Sandro Pignata</name></noRegion><name sortKey="Colombo, Nicoletta" sort="Colombo, Nicoletta" uniqKey="Colombo N" first="Nicoletta" last="Colombo">Nicoletta Colombo</name></country><country name="Allemagne"><noRegion><name sortKey="Harter, Philipp" sort="Harter, Philipp" uniqKey="Harter P" first="Philipp" last="Harter">Philipp Harter</name></noRegion></country><country name="Japon"><noRegion><name sortKey="Fujiwara, Keiichi" sort="Fujiwara, Keiichi" uniqKey="Fujiwara K" first="Keiichi" last="Fujiwara">Keiichi Fujiwara</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000692 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000692 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28754483
|texte= Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28754483" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |